The primary purpose of the Organic Synthesis Facility (OSF) is to produce the highest quality synthetic molecules for Fox Chase Cancer Center (FCCC) investigators. The OSF was used by 19 investigators with peer-reviewed funding in calendar year 2009. Over eighty-five percent (85.4%) of use was in support of peer-reviewed, funded investigators in calendar year 2009. Small organic molecules are used in many areas of research as specific reagents including those that are inhibitors of enzyme activity or protein binding. Some of these molecules have been used in the development of prodrugs against target proteins identified at FCCC. Analogues of natural substrates have been used to probe enzyme mechanism, to investigate protein function, or to lest specific hypotheses. The molecules synthesized by the Facility are not purchasable from chemical companies, and custom synthesis from commercial enterprises is either not available or prohibitively expensive. The demand for synthetic services and especially the demand for novel compound synthesis have increased significantly over this current funding period. In order to meet this need, the efficiency and productivity of the Facility have been increased with the addition of a seasoned Ph.D. chemist to the staff and by acquisition of a new LC-MS system. In addition to increasing efficiency, the LC-MS system provides the Facility with new capabilities and services. During the last grant period (calendar years 2006-2009), 79 different chemical syntheses were completed including 44 novel compounds for 17 investigators in four Research Programs. The compounds synthesized were very diverse in structure and included a series of tamoxifen analogues, drug-conjugated antibodies, p53 inhibitors, Paki inhibitors, and photosensitizers. The OSF provided analytical, purification and consulting services to 46 investigators from all five Research Programs and seven Shared Facilities during the current funding period. In the last four calendar years (2006-2009), the average number of requests for these analytical and purification services was 59 per month, compared to 34 in calendar years 2000-2004. The large user group of 46 investigators from all five Research Programs and seven Shared Facilities indicates that the materials produced and services provided by the Facility are necessary for the scientific objectives of a wide range of research projects being carried out throughout the Center.

Public Health Relevance

Macromolecular interactions are central to all biological processes, including those involved in the development of cancer. These interactions either directly involve small organic molecules or can be modified by them. Modern biological research therefore requires the availability of organic compounds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006927-48
Application #
8335542
Study Section
Subcommittee G - Education (NCI)
Project Start
2011-07-21
Project End
2014-06-30
Budget Start
2011-07-21
Budget End
2012-06-30
Support Year
48
Fiscal Year
2011
Total Cost
$30,031
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Gabbasov, Rashid; Xiao, Fang; Howe, Caitlin G et al. (2018) NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice. Oncogene 37:4854-4870
Nacson, Joseph; Krais, John J; Bernhardy, Andrea J et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep 24:3513-3527.e7
Fahl, Shawn P; Coffey, Francis; Kain, Lisa et al. (2018) Role of a selecting ligand in shaping the murine ??-TCR repertoire. Proc Natl Acad Sci U S A 115:1889-1894
Jones, Caitlin E; Hammer, Anisha M; Cho, YouJin et al. (2018) Stromal PTEN Regulates Extracellular Matrix Organization in the Mammary Gland. Neoplasia 21:132-145
Shaikh, Talha; Wang, Lora S; Egleston, Brian et al. (2018) Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer. Am J Clin Oncol 41:59-64
Campbell, Kerry S; Cohen, Adam D; Pazina, Tatiana (2018) Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma. Front Immunol 9:2551
Blackman, Elizabeth; Ashing, Kimlin; Gibbs, Denise et al. (2018) The Cancer Prevention Project of Philadelphia: preliminary findings examining diversity among the African diaspora. Ethn Health :1-17
Fatkhullina, Aliia R; Peshkova, Iuliia O; Dzutsev, Amiran et al. (2018) An Interleukin-23-Interleukin-22 Axis Regulates Intestinal Microbial Homeostasis to Protect from Diet-Induced Atherosclerosis. Immunity 49:943-957.e9
Gupta, Sapna; Kelow, Simon; Wang, Liqun et al. (2018) Mouse modeling and structural analysis of the p.G307S mutation in human cystathionine ?-synthase (CBS) reveal effects on CBS activity but not stability. J Biol Chem 293:13921-13931
Sementino, Eleonora; Menges, Craig W; Kadariya, Yuwaraj et al. (2018) Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas. J Cell Physiol 233:8952-8961

Showing the most recent 10 out of 1280 publications